SCHEMBL6841880

SCHEMBL6841880

O=C(NCc1ccccc1)c1ccc2c(c1)C(=O)c1cc(C(=O)NCc3ccccc3)ccc1-2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.68
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
GAA P10253 2/20 0.65
TSHR P16473 1/20 0.65
PTPRC P08575 2/20 0.62
CTSL P07711 1/20 0.62
PTPN13 Q12923 1/20 0.62
HPGD P15428 4/20 0.61
HSD17B10 Q99714 3/20 0.61
POLB P06746 1/20 0.61
MAPT P10636 1/20 0.61
PKM P14618 1/20 0.61
HDAC2 Q92769 2/20 0.59
HDAC8 Q9BY41 2/20 0.59
HDAC6 Q9UBN7 2/20 0.59
EGFR P00533 1/20 0.58
CA2 P00918 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
ADORA2A P29274 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17862109 0.84 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL29370025 0.82 ALDH1A1 (0.78) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL4158879 0.82 NPC1 (0.66) ALDH1A1PTPRCCTSLPTPN13HPGD
SCHEMBL11900090 0.81 HDAC6 (0.85) TSHRHPGDPOLBHDAC2HDAC8
SCHEMBL16431115 0.81 NPC1 (0.63) ALDH1A1MEN1KMT2AHPGDHSD17B10
SCHEMBL11902028 0.80 NR1H4 (0.79) ALDH1A1HPGDHSD17B10HDAC2HDAC8
SCHEMBL11900328 0.80 HDAC6 (0.87) ALDH1A1MEN1KMT2AGAAHPGD
SCHEMBL2915318 0.79 HDAC6 (0.74) ALDH1A1KMT2AHPGDHDAC2HDAC8
SCHEMBL7844926 0.79 ALDH1A1 (0.57) ALDH1A1MEN1KMT2AGAATSHR
SCHEMBL3589250 0.78 PTPRC (0.52) ALDH1A1MEN1KMT2APTPRCCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2004-04-01 US disclosed
EP-1360167-A1 SYMMETRICALLY DISUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING POLY (ADP-RIBOSE) GLYCOHYDROLASE, AND METHODS FOR THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2003-11-12 EP disclosed
US-6635786-B2 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2003-10-21 US disclosed
US-20020132852-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2002-09-19 US disclosed
WO-2002057211-A1 SYMMETRICALLY DISUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING POLY (ADP-RIBOSE) GLYCOHYDROLASE, AND METHODS FOR THEIR USE GUILFORD PHARMACEUTICALS, INC. (US) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use PARG, PARP1, PARP11 ALDH1A1 916/4885MEN1 3273/4885KMT2A 2020/4885
US-20020132852-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use PARG, PARP1, PARP11 ALDH1A1 916/4885MEN1 3273/4885KMT2A 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.